Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00337883
Status:
COMPLETED
Last Update Posted:
2014-03-04
First Post:
2006-06-15
Brief Title:
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma Glioblastoma Multiforme
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Multicenter Open-Label Trial of the Safety and Efficacy of Tarceva Erlotinib Hydrochloride in Patients With First Relapse of Grade IV Glioma Glioblastoma Multiforme
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II open-label multicenter trial of single-agent treatment with Tarceva in patients with histologically confirmed GBM in first relapse This study seeks to estimate the objective response rate and will investigate whether response rate is related to EGFR amplification status
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None